Literature DB >> 18652998

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings.

Graeme Meintjes1, Stephen D Lawn, Fabio Scano, Gary Maartens, Martyn A French, William Worodria, Julian H Elliott, David Murdoch, Robert J Wilkinson, Catherine Seyler, Laurence John, Maarten Schim van der Loeff, Peter Reiss, Lut Lynen, Edward N Janoff, Charles Gilks, Robert Colebunders.   

Abstract

The immune reconstitution inflammatory syndrome (IRIS) has emerged as an important early complication of antiretroviral therapy (ART) in resource-limited settings, especially in patients with tuberculosis. However, there are no consensus case definitions for IRIS or tuberculosis-associated IRIS. Moreover, previously proposed case definitions are not readily applicable in settings where laboratory resources are limited. As a result, existing studies on tuberculosis-associated IRIS have used a variety of non-standardised general case definitions. To rectify this problem, around 100 researchers, including microbiologists, immunologists, clinicians, epidemiologists, clinical trialists, and public-health specialists from 16 countries met in Kampala, Uganda, in November, 2006. At this meeting, consensus case definitions for paradoxical tuberculosis-associated IRIS, ART-associated tuberculosis, and unmasking tuberculosis-associated IRIS were derived, which can be used in high-income and resource-limited settings. It is envisaged that these definitions could be used by clinicians and researchers in a variety of settings to promote standardisation and comparability of data.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652998      PMCID: PMC2804035          DOI: 10.1016/S1473-3099(08)70184-1

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  42 in total

1.  Mycobacterium-associated immune reconstitution disease: macrophages running wild?

Authors:  Rafael Van den Bergh; Guido Vanham; Geert Raes; Patrick De Baetselier; Robert Colebunders
Journal:  Lancet Infect Dis       Date:  2006-01       Impact factor: 25.071

2.  A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis.

Authors:  Justine Dautremer; Jérôme Pacanowski; Pierre-Marie Girard; Valérie Lalande; Françoise Sivignon; Jean-Luc Meynard
Journal:  AIDS       Date:  2007-01-30       Impact factor: 4.177

Review 3.  Scaling up antiretroviral treatment in resource-limited settings: successes and challenges.

Authors:  Elly T Katabira; Robert B Oelrichs
Journal:  AIDS       Date:  2007-07       Impact factor: 4.177

4.  Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden.

Authors:  Maryline M B Bonnet; Loretxu L P Pinoges; Francis F V Varaine; Barbara B O Oberhauser; Daniel D O O'Brien; Yared Y K Kebede; Cathy C H Hewison; Rony R Z Zachariah; Laurent L F Ferradini
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

5.  Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease.

Authors:  J Olalla; F Pulido; R Rubio; M A Costa; R Monsalvo; E Palenque; J R Costa; Palacio A Del
Journal:  Int J Tuberc Lung Dis       Date:  2002-01       Impact factor: 2.373

6.  Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy.

Authors:  Jaime Robertson; Matthew Meier; Jennifer Wall; Jun Ying; Carl J Fichtenbaum
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

7.  Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

Authors:  Guillaume Breton; Xavier Duval; Candice Estellat; Xavier Poaletti; Daniel Bonnet; David Mvondo Mvondo; Pascale Longuet; Catherine Leport; Jean-Louis Vildé
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

8.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.

Authors:  David Coetzee; Katherine Hildebrand; Andrew Boulle; Gary Maartens; Francoise Louis; Veliswa Labatala; Hermann Reuter; Nonthutuzelo Ntwana; Eric Goemaere
Journal:  AIDS       Date:  2004-04-09       Impact factor: 4.177

Review 9.  Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.

Authors:  Helen McIlleron; Graeme Meintjes; William J Burman; Gary Maartens
Journal:  J Infect Dis       Date:  2007-08-15       Impact factor: 5.226

10.  Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis.

Authors:  Christos Michailidis; Anton L Pozniak; Sundhiya Mandalia; Sheena Basnayake; Mark R Nelson; Brian G Gazzard
Journal:  Antivir Ther       Date:  2005
View more
  264 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

3.  Fighting the monster.

Authors:  Amy Maxmen
Journal:  Nature       Date:  2010-07-15       Impact factor: 49.962

4.  Immune reconstitution inflammatory syndrome.

Authors:  M S Barthwal; Yadvir Garg; D Bhattacharya; C D S Katoch; A K Rajput; V Marwah
Journal:  Med J Armed Forces India       Date:  2014-10-08

Review 5.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 6.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

7.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

Review 8.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

9.  TB-IRIS, T-cell activation, and remodeling of the T-cell compartment in highly immunosuppressed HIV-infected patients with TB.

Authors:  Viraga Haridas; Polidy Pean; Luke D Jasenosky; Yoann Madec; Didier Laureillard; Thim Sok; Sun Sath; Laurence Borand; Olivier Marcy; Sarin Chan; Erdyni Tsitsikov; Jean-François Delfraissy; François-Xavier Blanc; Anne E Goldfeld
Journal:  AIDS       Date:  2015-01-28       Impact factor: 4.177

10.  Hospitalization risk following initiation of highly active antiretroviral therapy.

Authors:  S A Berry; Y C Manabe; R D Moore; K A Gebo
Journal:  HIV Med       Date:  2009-12-08       Impact factor: 3.180

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.